Sumitomo Dainippon Pharma (4506) reports robust FY2025 results, posts record net profit
Sumitomo Pharma Co., Ltd. (4506) shares advanced today after the company reported robust financial results for its 2025 fiscal year on 13 May 2026. The Japanese pharmaceutical firm's stock is trading at ¥1,612, up 6.0% from its previous close of ¥1,520.
The company posted a record net profit of ¥106.9 billion for fiscal year 2025, with revenue climbing 13.7% to ¥453.3 billion. This performance was largely attributed to strong sales of its key products, ORGOVYX and GEMTESA, in the United States. Sumitomo Pharma also provided an optimistic outlook for fiscal years 2027 and 2028.
Today's upward movement marks a rebound from recent weakness. Last week, the stock declined after SMBC Nikko Securities withdrew its underwriting of a capital increase. Further concerns over a projected decline in gross profit margins and the burden of a public offering led to a 4.4% drop on 20 May 2026.
Why Strong Results Overcame Prior Market Doubts
Sumitomo Pharma is a major Japanese pharmaceutical company involved in the research, development, manufacturing, and sale of medicines. It primarily provides treatments for conditions such as cancer and central nervous system disorders to medical institutions and patients. Sales of key products like ORGOVYX and GEMTESA, particularly in the US market, support the company's revenue.
Today's specific factor driving up the share price is the strong financial results for fiscal year 2025, announced on 13 May 2026. The company reported a record net profit of ¥106.9 billion and a 13.7% increase in revenue from the previous period, reaching ¥453.3 billion. This was driven by strong sales of ORGOVYX and GEMTESA in the United States, and an optimistic earnings outlook has also been presented for fiscal years 2027 and 2028. Recently, the share price had been sluggish due to concerns such as the cancellation of the capital increase underwriting by SMBC Nikko Securities, the outlook for lower gross profit margins despite good results, and the burden of a public offering, even recording a 4.4% decline on 20 May 2026.
Against this backdrop, a robust earnings announcement and confidence in the future, which dispelled market concerns, pushed Sumitomo Pharma's share price up by 6.0% today, from yesterday's closing price of ¥1,520 to ¥1,612.
This is much like a market that was awaiting the launch of a new product, initially somewhat sceptical of its early reviews. However, once the product was actually released, it delivered sales and profits far exceeding expectations, clearly demonstrating its future growth potential. As a result, previous concerns were dispelled, and the product's true value and future prospects were re-evaluated.
Sumitomo Dainippon Pharma Co., Ltd.
Sumitomo Pharma Co., Ltd. (4506), a subsidiary of Sumitomo Chemical Company, Limited, operates in the Healthcare sector, specialising in Drug Manufacturers - Specialty & Generic. The Japanese pharmaceutical firm develops and markets a diverse portfolio of products, including treatments for Parkinson's disease, depression, and type 2 diabetes, alongside atypical antipsychotics and carbapenem antibiotics. Beyond pharmaceuticals, Sumitomo Pharma manufactures food ingredients such as polysaccharides and seasonings, as well as chemical product materials for personal care, coatings, and electronics. The company also supplies veterinary medicines for companion animals and livestock. With a global presence spanning Japan, North America, China, and other international markets, Sumitomo Pharma engages in various strategic partnerships, including collaborations with Healios K.K., Keio University, and Otsuka Pharmaceutical Co., Ltd. The company was founded in 1897 and is headquartered in Osaka, Japan.